Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (2018 - 2025)

BioNexus Gene Lab's Shares Outstanding history spans 8 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding changed 0.01% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, changed 0.01%, while the annual FY2024 figure was $1.8 million, 1.7% up from the prior year.
  • Shares Outstanding for Q3 2025 was $1.8 million at BioNexus Gene Lab, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $171.2 million in Q1 2021 and bottomed at $1.8 million in Q4 2023.
  • The 5-year median for Shares Outstanding is $14.3 million (2021), against an average of $34.0 million.
  • The largest annual shift saw Shares Outstanding plummeted 91.67% in 2021 before it increased 22.91% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $14.3 million in 2021, then rose by 1.46% to $14.5 million in 2022, then plummeted by 87.8% to $1.8 million in 2023, then increased by 1.7% to $1.8 million in 2024, then decreased by 0.01% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Shares Outstanding are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $1.8 million (Q1 2025).